Hisun Pfizer Pharmaceuticals Co., Ltd. was co-founded by Zhejiang Hisun Pharmaceutical Co., Ltd., the leading pharmaceutical enterprise in China, and Hillhouse Capital Group, the world-leading investment management agency. The company develops, produces and popularizes high-quality branded generics and off-patent original drugs which comply with international standards. Its revenue ranks among the top 50 in China’s pharmaceutical industry. 

Hisun Pfizer was established in 2012 with an investment of $295 million and a registered capital of $250 million. The operation center is located in Shanghai, with more than 2,200 employees. The company’s products are sold in 31 provinces and autonomous regions, over 1,350 cities and counties, and over 13,000 hospitals. 

The company owns more than 80 kinds of products, including world-leading original products and ones that have won the National Award for Technological Invention. They cover the fields of tumors, antibiotics, angiocarpy, diabetes, hormone treatments and immune transplants. 

The Fuyang manufacturing base of Hisun Pfizer has six advanced production lines for oral and freeze-dried preparations, and has attained the certification of the Pfizer Global Quality System (PQS) which is the strictest in the world. The base is the GMP inspector training base of the CFDA food and drug inspection center. Its production line of oral preparations passed an FDA on-the-spot audit in December 2015 and November 2016.